Key figures as of December 31, 2017


Cash, cash equivalents and financial assets*


* Including current and non-current financial assets

Financial debt



>180 employees, 3/4 of whom are dedicated to R&D


  • 4 programs in clinical stage including one licensed to Bristol-Myers Squibb and one partnered with AstraZeneca
  • 1 portfolio of proprietary preclinical programs

See FY 2017 financial results

See HY 2017 financial results